Vimarsana
Biggest News Aggregation in the World

Page 25 - Mployee Wellness Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mployee Wellness Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mployee Wellness Programs Today - Breaking & Trending Today

Believing Amazon's Job Cuts Signal an Exit From Healthcare Would Be 'Overly Simplistic,' Expert Says - Vimarsana News

Believing Amazon's Job Cuts Signal an Exit From Healthcare Would Be 'Overly Simplistic,' Expert Says

Amazon has eliminated “a few hundred” jobs across Amazon Pharmacy and One Medical, the company confirmed to MedCity News Wednesday. While some may believe this could lead to Amazon leaving healthcare, one industry expert said that would be an "overly simplistic" takeaway.

MedCity News Launches Debunked, A Show Where We Slaughter Myths, Bad Practices and Sacred Cows in Healthcare - Vimarsana News

MedCity News Launches Debunked, A Show Where We Slaughter Myths, Bad Practices and Sacred Cows in Healthcare

MedCity News is launching a new ongoing show called Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare. In this show, co-hosts Arundhati Parmar and Samir Batra will discuss healthcare news and call out things that seem utterly insane to us. The goal is to inspire change in the healthcare industry.

Five Ways AI Will Impact Clinical Trials This Year - Vimarsana News

Five Ways AI Will Impact Clinical Trials This Year

The integration of AI technologies holds promise for enhancing outreach efforts, streamlining recruitment processes, and addressing long-standing barriers and biases that hinder diversity and inclusion in clinical trials.

BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies - Vimarsana News

BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies

Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive - Vimarsana News

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive

Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug's potential competitiveness in a crowded field of contenders.